The Trump administration has pledged $812 million (AED 2.98 billion) to boost the US manufacturing of medicines needed to treat the coronavirus.
It's aimed to end dependence on other countries, and boost their own supply chain.
The four-year contract, worth $354 million, which has been awarded to Virginia-based Phlow Corp can be extended to a total of $812 million over 10 years.
It will develop essential drugs and not vaccines, officials explained.
"For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk," Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said in a statement.
US lets flights resume at El Paso airport after brief security halt
Ten dead after shooter opens fire at high school in Canada
Tropical cyclone Gezani slams into Madagascar, killing nine
Russian strike kills father and three children near Ukraine's Kharkiv
Cambodia says it has closed almost 200 scam centres in fraud crackdown
